Good news has been scarce for this beaten-down drugmaker.

Up until recently, the stock has been a chronic underperformer.

TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 24, ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or ...

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...

Pfizer has reached a turning point.

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s latest stock calls as he discussed the bullish AI investment thesis amid the ...